The protective impact of glutamine on anti-tuberculosis drug-induced nephrotoxicity in Wistar rats

Q3 Medicine

Tokai Journal of Experimental and Clinical Medicine Pub Date : 2023-03-18 DOI:10.52142/omujecm.40.1.2

Elias Adikwu, Martins Mbonu, Tobechi Brendan Nnanna

{"title":"The protective impact of glutamine on anti-tuberculosis drug-induced nephrotoxicity in Wistar rats","authors":"Elias Adikwu, Martins Mbonu, Tobechi Brendan Nnanna","doi":"10.52142/omujecm.40.1.2","DOIUrl":null,"url":null,"abstract":"This study assessed the protective effect of glutamine (GTN) against rifampicin/isoniazid/pyrazinamide/ethambutol (RIPE)-induced nephrotoxicity in rats. Thirty adult Wistar rats (200±20 g) of both sexes were grouped into 6 of 5 rats/group. The rats were treated daily for 30 days as follows: Group 1 (Vehicle control [normal saline 0.2mL]), group 2 (GTN 200 mg/kg), group 3 (RIPE 150, 75, 400 and 275 mg/kg in vehicle), group 4 (GTN 50 mg/kg +RIPE), group 5 (GTN 100 mg/kg +RIPE) and group 6 (GTN 200 mg/kg +RIPE). After treatment, blood samples were obtained and assessed for serum renal biomarkers. Kidneys were harvested, weighed and assessed for oxidative stress markers and histology. RIPE significantly (p<0.01) decreased body weight and significantly (p<0.01) increased kidney weight when compared to the control. Serum urea, creatinine, uric acid levels and kidney malondialdehyde levels were significantly (p<0.001) increased in RIPE-treated rats when compared to the control. Serum total protein, albumin, kidney glutathione, catalase, superoxide dismutase and glutathione peroxidase levels were significantly decreased (p<0.001) in RIPE-treated rats when compared to the control. RIPE caused tubular necrosis and collapsed glomeruli in the kidneys of rats. However, body and liver weights were significantly restored in GTN 100 mg/kg +RIPE and GTN 200 mg/kg +RIPE-treated rats at p<0.05 and p<0.01, respectively when compared to RIPE. Serum and kidney oxidative stress markers were restored in GTN 50 mg/kg +RIPE, GTN 100 mg/kg +RIPE and GTN 200 mg/kg +RIPE-treated rats at p<0.05, p<0.01 and p<0.001 respectively, when compared to RIPE. GTN restored kidney histology. GTN protects against RIPE-induced nephrotoxicity in a dose-related fashion.","PeriodicalId":38819,"journal":{"name":"Tokai Journal of Experimental and Clinical Medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tokai Journal of Experimental and Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52142/omujecm.40.1.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

This study assessed the protective effect of glutamine (GTN) against rifampicin/isoniazid/pyrazinamide/ethambutol (RIPE)-induced nephrotoxicity in rats. Thirty adult Wistar rats (200±20 g) of both sexes were grouped into 6 of 5 rats/group. The rats were treated daily for 30 days as follows: Group 1 (Vehicle control [normal saline 0.2mL]), group 2 (GTN 200 mg/kg), group 3 (RIPE 150, 75, 400 and 275 mg/kg in vehicle), group 4 (GTN 50 mg/kg +RIPE), group 5 (GTN 100 mg/kg +RIPE) and group 6 (GTN 200 mg/kg +RIPE). After treatment, blood samples were obtained and assessed for serum renal biomarkers. Kidneys were harvested, weighed and assessed for oxidative stress markers and histology. RIPE significantly (p<0.01) decreased body weight and significantly (p<0.01) increased kidney weight when compared to the control. Serum urea, creatinine, uric acid levels and kidney malondialdehyde levels were significantly (p<0.001) increased in RIPE-treated rats when compared to the control. Serum total protein, albumin, kidney glutathione, catalase, superoxide dismutase and glutathione peroxidase levels were significantly decreased (p<0.001) in RIPE-treated rats when compared to the control. RIPE caused tubular necrosis and collapsed glomeruli in the kidneys of rats. However, body and liver weights were significantly restored in GTN 100 mg/kg +RIPE and GTN 200 mg/kg +RIPE-treated rats at p<0.05 and p<0.01, respectively when compared to RIPE. Serum and kidney oxidative stress markers were restored in GTN 50 mg/kg +RIPE, GTN 100 mg/kg +RIPE and GTN 200 mg/kg +RIPE-treated rats at p<0.05, p<0.01 and p<0.001 respectively, when compared to RIPE. GTN restored kidney histology. GTN protects against RIPE-induced nephrotoxicity in a dose-related fashion.

查看原文本刊更多论文

谷氨酰胺对Wistar大鼠抗结核药物肾毒性的保护作用

本研究评估了谷氨酰胺(GTN)对利福平/异烟肼/吡嗪酰胺/乙胺丁醇(RIPE)所致大鼠肾毒性的保护作用。雄性和雌性成年Wistar大鼠30只(200±20 g)，每组5只，随机分为6只。每天按以下方法给药30 d: 1组(载药对照[生理盐水0.2mL])、2组(GTN 200 mg/kg)、3组(载药熟150、75、400、275 mg/kg)、4组(GTN 50 mg/kg +RIPE)、5组(GTN 100 mg/kg +RIPE)、6组(GTN 200 mg/kg +RIPE)。治疗后，采集血液样本并评估血清肾生物标志物。取肾，称重并评估氧化应激标志物和组织学。与对照组相比，RIPE显著(p<0.01)降低了体重，显著(p<0.01)增加了肾脏重量。与对照组相比，ripe处理大鼠血清尿素、肌酐、尿酸水平和肾脏丙二醛水平显著(p<0.001)升高。与对照组相比，ripe处理大鼠血清总蛋白、白蛋白、肾谷胱甘肽、过氧化氢酶、超氧化物歧化酶和谷胱甘肽过氧化物酶水平显著降低(p<0.001)。RIPE引起大鼠肾小管坏死和肾小球塌陷。GTN 100 mg/kg +RIPE组和GTN 200 mg/kg +RIPE组大鼠体重和肝重较RIPE组显著恢复(p<0.05和p<0.01)。与RIPE相比，GTN 50 mg/kg +RIPE、GTN 100 mg/kg +RIPE和GTN 200 mg/kg +RIPE处理大鼠血清和肾脏氧化应激标志物恢复率分别为p<0.05、p<0.01和p<0.001。GTN恢复肾脏组织学。GTN以剂量相关的方式防止ripe诱导的肾毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tokai Journal of Experimental and Clinical Medicine Medicine-Medicine (all)

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.